Please assess the completion status of the following clinical trial:

Trial Title: Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB or Stage IV NSCLC~* Stable disease or a clinical response following first-line treatment, consisting of either chemotherapy alone or chemotherapy and radiotherapy. Subjects must have completed the first-line treatment at least 3 weeks prior to study entry~* Eastern Cooperative Oncology Group (ECOG) performance status of greater than or equal to (\>=) 2~* Ability to understand and willingness to sign a written informed consent~* Other protocol-defined inclusion criteria could apply~Exclusion Criteria:~* Received immunotherapy within 4 weeks prior to study entry~* Received immunosuppressive drugs within 3 weeks prior to study entry~* Subjects with known brain metastases~* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years~* Autoimmune disease or immunodeficiency~* Clinically significant hepatic, renal or cardiac dysfunction~* Subjects with clinically significant active infection~* Pregnant or breast feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator~* Other protocol-defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tecemotide (L-BLP25) plus Best Supportive Care (BSC) (Type: EXPERIMENTAL): None
- Best Supportive Care (BSC) Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).